Former champion billiards player Jeanette Lee, 53, is living with stage 4 ovarian cancer and manages by taking Lynparza.

AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. As with other drugs, Elahere can cause side effects, such as eye problems ...

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen for $10 billion last year), Sutro thinks its "best in class" candidate ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.